Press Releases

Date Title
9/7/18 Sarepta Therapeutics to Recognize World Duchenne Awareness Day at NASDAQ Opening Bell Ceremony
9/4/18 Sarepta Therapeutics to Present at Two Upcoming Investor Conferences
8/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/20/18 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
8/8/18 Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments
8/8/18 Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools
7/31/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7/25/18 Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) Micro-Dystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events
7/20/18 Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018
6/29/18 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 81 - 90 of 620